Psoriasis News and Research

Latest Psoriasis News and Research

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced 52-week results from PALACE 1, the Company's first phase III study in psoriatic arthritis at the European Congress of Rheumatology annual meeting in Madrid, Spain.

12 Jun 2013

Six top scientists studying psoriasis receive NPF research grants to discover new treatments for chronic diseases

Six of the top scientists studying psoriasis-the most common autoimmune disease in the country, affecting 7.5 million Americans-and psoriatic arthritis, an inflammatory joint and tendon disease affecting up to 30 percent of people with psoriasis, received National Psoriasis Foundation (NPF) research grants totaling $450,000 for projects that aim to discover new treatments and a cure for these chronic diseases.

5 Jun 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013

XenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3 clinical trial

XenoPort, Inc. announced today top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil for the treatment of patients with spasticity due to multiple sclerosis.

20 May 2013

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.

17 May 2013

Researchers explain why cost of care higher for men with severe psoriasis

Men often suffer from more severe cases of psoriasis than women, which may explain why the cost of care for men is higher. This is the conclusion of researchers at Umeå University in a new study.

16 May 2013

Implications for manipulating immune response for some inflammatory disorders

Cytokines are molecules produced by immune cells that induce the migration of other cells to sites of infection or injury, promote the production of anti-microbial agents, and signal the production of inflammatory mediators.

14 May 2013

Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

Biogen Idec announced today that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for the marketing approval of ELOCTATE (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A.

13 May 2013

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

Prednisone and non-steroidal anti-inflammatory drugs (NSAIDs) can be used for symptom control, but to prevent joint damage, we use disease-modifying anti-rheumatic drugs (DMARDs) including the cornerstone, methotrexate.

13 May 2013

Headline results of Creabilis' CT327 Phase 2b trial in psoriasis patients announced

Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients.

10 May 2013

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.

8 May 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

Osteomyelitis guidelines push pediatric care

US clinicians have demonstrated the benefits of multidisciplinary evidence-based guidelines for the treatment of children with osteomyelitis.

29 Apr 2013

Genes play role in wound healing, regulate biological processes in human skin

Biologists at UC San Diego have identified eight genes never before suspected to play a role in wound healing that are called into action near the areas where wounds occur.

26 Apr 2013

Experts and patients share tips on preventing skin cancer

Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers.

26 Apr 2013

Calcipotriol drug offers a potential treatment option for fibrotic diseases

Liver fibrosis results from an excessive accumulation of tough, fibrous scar tissue and occurs in most types of chronic liver diseases. In industrialized countries, the main causes of liver injury leading to fibrosis include chronic hepatitis virus infection, excess alcohol consumption and, increasingly, nonalcoholic steatohepatitis (NASH).

26 Apr 2013

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

XBiotech announced today enrollment of the first patient into its Phase III trial of Xilonix. The Pivotal study is designed to improve health and survival of late stage colorectal cancer patients with associated cachexia.

25 Apr 2013

Nuvo Research reaches another milestone with the launch of Pliaglis in Europe

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A., today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.

23 Apr 2013

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Researchers have newly associated nine genetic regions with a rare autoimmune disease of the liver known as primary sclerosing cholangitis (PSC). This brings the total number of genetic regions associated with the disease to 16.

22 Apr 2013

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

Patients with rheumatoid arthritis (RA) who initiated use of anti-tumor necrosis factor therapies were not at a higher risk of developing herpes zoster (shingles), compared with patients who initiated nonbiologic treatment regimens, according to research from the University of Alabama at Birmingham (UAB) and the Oregon Health and Science University. The findings appeared in the March 6, 2013, issue of the Journal of the American Medical Association (JAMA).

22 Apr 2013

Psoriasis News and Research

Latest Psoriasis News and Research

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Six top scientists studying psoriasis receive NPF research grants to discover new treatments for chronic diseases

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

XenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3 clinical trial

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Researchers explain why cost of care higher for men with severe psoriasis

Implications for manipulating immune response for some inflammatory disorders

Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

Headline results of Creabilis' CT327 Phase 2b trial in psoriasis patients announced

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Osteomyelitis guidelines push pediatric care

Genes play role in wound healing, regulate biological processes in human skin

Experts and patients share tips on preventing skin cancer

Calcipotriol drug offers a potential treatment option for fibrotic diseases

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

Nuvo Research reaches another milestone with the launch of Pliaglis in Europe

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Psoriasis News and Research

Latest Psoriasis News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Newsletters you may be interested in